Prevalence of renal abnormalities in chronic HBV infection: The HARPE study. (3rd March 2014)

• Record Type: Journal Article
• Authors: Amet, Sabine; Bronowicki, Jean‐Pierre; Thabut, Dominique; Zoulim, Fabien; Bourliere, Marc; Mathurin, Philippe; de Ledinghen, Victor; Benhamou, Yves; Larrey, Dominique G.; Janus, Nicolas; Deray, Gilbert; Launay‐Vacher, Vincent; Pol, Stanislas
• Is Part Of: Liver international. Volume 35(2015)Supplement 1
• Page Start: 148
• Page End: 155
• Publication Date: 2014-03-03
• Subjects: Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.12480
• Languages: English
• ISSNs: 1478-3223

Abstract

<abstract abstract-type="main" id="liv12480-abs-0001"> <title>Abstract</title> <sec id="liv12480-sec-0001" sec-type="section"> <title>Background & Aims</title> <p>Few data are available on the prevalence of renal abnormalities in chronic hepatitis B virus (HBV)‐infected patients. The multicentric cross‐sectional HARPE study evaluated the prevalence of kidney disease indicators, in chronic HBV surface antigen carriers patients (HBsAg+) with active or inactive infection.</p> </sec> <sec id="liv12480-sec-0002" sec-type="section"> <title>Patients and methods</title> <p>Two hundred and sixty‐eight HBsAg+ adult patients, naïve of any oral antihepatitis B virus treatment were prospectively included over 2 years. Data for renal assessment were collected once from patient files. Univariate tests and multiple linear regressions were performed with the SAS software, version 8.02 (SAS, Inc., Cary, NC, USA).</p> </sec> <sec id="liv12480-sec-0003" sec-type="section"> <title>Results</title> <p>Among the 260 patients analysed, 58% were men, the mean age was 42 ± 14 years, 59.6% were inactive carriers whereas 47 patients, mostly active, were about to start an antiviral therapy. Prevalence of proteinuria, haematuria, glycosuria, uninfectious leukocyturia was 38.1%, 20.6%, 3.9% and 9% respectively. According to the international definition, a total of 64.6% of patients were found to have kidney disease. Diabetes, hypertension and dyslipidaemia were observed, respectively, in 4.6%, 9.2% and 38.8% patients. There were no significant differences in these results within the three subgroups.</p> </sec> <sec id="liv12480-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Renal abnormalities are highly prevalent in our population and pre‐exist before the initiation of any antihepatitis B virus treatment. This emphasizes the need for: (i) a baseline renal evaluation in all HBs antigen‐positive patients; (ii) a regular renal monitoring before and during antihepatitis B virus treatment to diagnose and manage renal impairment and adjust antihepatitis B virus treatment doses to renal function when necessary.</p> </sec> </abstract>